Posted on 09/13/2022 2:16:06 PM PDT by ConservativeMind
Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional chemotherapy, according to results presented today by researchers from The University of Texas MD Anderson Cancer Center at the European Society for Medical Oncology (ESMO) Congress 2022.
Based on pre-defined patient reported outcome measures, researchers found that the time to definitive deterioration (TDD) for global health status/QoL with T-DXd was 11.4 months, compared to just 7.5 months with a physician's choice of chemotherapy, signifying that T-DXd treatment delays the decline of QoL in patients with metastatic breast cancer.
"The DESTINY-Breast04 study reported improved progression-free survival and response rates and was practice-changing for patients with HER2-low metastatic breast cancer," said presenting author Naoto Ueno, M.D., Ph.D., professor of Breast Medical Oncology. "We know the treatment was effective, but we wanted to hear from patients themselves to better understand how patients tolerated the treatment and how it impacted their overall health."
Patients enrolled in DESTINY-Breast04 were asked to complete questionnaires about their health-related QoL before, during and after treatment. Nearly all patients completed the three validated questionnaires at the start of the study, and at least 80% completed them at the specified time points for treatment cycles 2 to 27.
The pain symptom scale showed a time to definitive deterioration of 16.4 months for patients who received T-DXd compared to only 6.1 months in those who received chemotherapy, which is important since pain is known to have a profound impact on patients' QoL.
For patients who were treated with T-DXd, global health status/QoL was maintained over the course of treatment, suggesting that treatment did not decrease patients' reported health-related QoL.
(Excerpt) Read more at medicalxpress.com ...
Can you trust a treatment you can’t pronounce?
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.